DNCA

DNCA is a neutral lipid that has been used in the generation of lipid nanoparticles (LNPs).¹ Intravenous administration of LNPs containing DNCA and encapsulating siRNA targeting BRAF containing a valine-to-glutamate substitution at position 600 (BRAF^V600E) reduce tumor BRAF^V600E expression and tumor weight and volume without reducing animal weight in an A375 melanoma mouse xenograft model. Intratumoral administration of LNPs containing DNCA and encapsulating cyclic di-GMP decreases tumor volume, increase survival, and increase the ratio of tumor-associated cytotoxic/exhausted CD4⁺ and CD8⁺ T cells in an EO771 murine model of primary breast cancer with tumor rechallenge.²